Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.
AI Summary & Key Takeaways
- The round valued the AI biotech at $2 billion
- It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.
Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
Related stories
How OpenAI turned its coding tools into dots, an always-on personal assistant
Alexander Embiricos, the OpenAI executive responsible for dots, never wants to have a meeting with someone else's AI agent.
It's happening...
One of the most controversial companies in history just filed to go public. And yes, we're talking about Anthropic. The same company that says there's a greater than 10% chance AI kills all of humanity is also simultaneously one of the best built businesses of all time. And in…
The New Full-Stack Designer
Today, I'm joined by Marvin Schwaibold, who leads the product design studio at Shopify. He'll give us a behind-the-scenes look at his process, >> [music] >> where we'll see how he's using the latest AI tools to bring his designs to life, then review some viewer-submitted…
Anthropic files for IPO
The placement volume and price per share have not yet been announced